Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The M.D. Anderson experience

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 6, 1999, Pages 471-478

  Ibrahim, Nuhad K ^a   Hortobagyi, Gabriel N ^a   Ewer, Michael ^b   Ali, Mohammed K ^b   Asmar, Lina ^a   Theriault, Richard L ^a   Fraschini, Giuseppe ^a   Frye, Debra K ^a   Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Congestive heart failure; Doxorubicin; Elderly; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; AGING; ARTICLE; BREAST CANCER; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIAGNOSTIC APPROACH ROUTE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 0032946808     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050926     Document Type: Article

References (57)

1. Jaenke RS (1974) An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 30: 292
2. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL (1974) Electrolyte and morphologic alterations of myocardium in Adriamycin-treated rabbits. Am J Pathol 77: 439
3. Billingham ME, Bristow MR, Mason JW, Friedman M (1976) Endomyocardial biopsy findings in adriamycin-treated patients. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 17: 281
4. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32: 302
5. Buja LM, Ferraus VJ, Mayer RJ, Roberts WC, Henderson ES (1973) Cardiac ultrastructural changes induced by doxorubicin therapy. Cancer 32: 771
6. Gottlieb JA, Lefrak EA, O'Bryan RM, Burgess MA (1973) Fatal Adriamycin cardiomyopathy: prevention by dose limitation. Proc Am Assoc Cancer Res 14: 88
7. Blum RH, Carter SK (1974) Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 80: 249
8. Rinehart JJ, Lewis RP, Balcerzak SP (1974) Adriamycin cardiotoxicity in man. Ann Intern Med 81: 475
9. Minow RA, Benjamin RS, Gottlieb JA (1975) Adriamycin (NSC-123127) cardiomyopathy: an overview with determination of risk factors. Cancer Chemother Rep 6: 195
10. Minow RA, Benjamin RS, Lee ET, Gottlieb JA (1977) Adriamycin cardiomyopathy: risk factors. Cancer 39: 1397
11. Cortes EP, Lutman G, Wanka J, Wang JJ, Pickren J, Wallace J, Holland JF (1975) Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother Rep 6: 215
12. Lefrak EA, Pitha J, Rosenheim S, O'Bryan RM, Burgess MA, Gottlieb JA (1975) Adriamycin (NSC-123127) cardiomyopathy. Cancer Chemother Rep 6: 203
13. Minow RA, Benjamin RS, Lee ET, Gottlieb JA (1978) QRS voltage change with Adriamycin administration. Cancer Treat Rep 62: 931
14. Jaenke RS (1976) Delayed and progressive myocardial lesions after adriamycin administration in rabbits. Cancer Res 36: 2958
15. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88: 168
16. Billingham ME, Birstow MR, Glastein E, Mason JW, Masek MA, Daniels JR (1977) Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1: 17
17. Merrill J, Greco FA, Zimbler H, Brereton HD, Lamberg JD, Pomeroy TC (1975) Adriamycin and radiation: synergistic cardiotoxicity (letter). Ann Intern Med 82: 122
18. Prout MN, Richards MJS, Chung KJ, Joo P, Davis HL Jr (1977) Adriamycin cardiotoxicity in children: case reports, literature review, and risk factors. Cancer 39: 62
19. Gilladoga AC, Manuel C, Tan CC, Wollner N, Murphy ML (1975) Cardiotoxicity of adriamycin (NSC-123127) in children. Cancer Chemother Rep 6: 209
20. Cupples LA, D'Agostino RB (1987) Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham heart study, 30-years followup. In: Kannel WB, Wolf PA, Garrison RT (eds) The Framingham study: an epidemiological investigation of cardiovascular diseases. (NIH No. 87-2703) National Heart, Lung and Blood Institute
21. Hankey BF (1992) Breast, Section IV In: Miller BA, Ries LAG, Hankey BF, et al (eds) Cancer statistics review 1973-1989. (NIH No. 92-1789) National Cancer Institute, Bethesda
22. Buzdar AU, Hortobagyi GN, Singletary SE, Holmes FA, Theriault R, Walters R, Dhingra K, Booser D, Morris A, Asmar L, Wright-Browne V, Diamandidou E, Witjaksono MA, Strom E, McNeese M, Ames F (1997) Impact of FAC-adjuvant therapy on mortality of early breast cancer: long-term results of the M.D. Anderson Cancer Center studies. In: Salmon SE (ed) Adjuvant therapy of cancer VIII. Lippincott-Raven. Philadelphia, p 93
23. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197
24. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688
25. Blumenschein GR, Cardenas JO, Freireich EJ, Gottlieb JA (1974) FAC chemotherapy for breast cancer. Proc Am Assoc Cancer Res 15: 193
26. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM (1979) Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG. Cancer 43: 1225
27. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY, Schell FC, Barnes BC, Burgess MA (1981) Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol 18: 163
28. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM (1978) Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin. Cancer Treat Rep 62: 1685
29. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM (1979) Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer 43: 1112
30. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM (1980) Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCF or MER BCG for advanced breast carcinoma. Cancer 45: 742
31. Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP (1979) Ftorafur, Adriamycin, cyclophosphamide, and BCG in the treatment of metastatic breast cancer. Cancer 44: 398
32. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP (1979) Ifosf-amide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 63: 115
33. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR (1987) High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 5: 178
34. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, Buzdar AU, Legha SS, Gutterman JU, Hersh EM, Bodey GP (1980) Chemoimmunotherapy for metastatic breast cancer with 5-FU, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep 64: 157
35. Legha SS, Blumenschein GR, Hortobagyi G, Buzdar A, Yap H, Bodey G (1982) Treatment of metastatic breast carcinoma causing a combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and tamoxifen. In: Proceedings of the 18th Annual Meeting of the American Society of Clinical Oncology, vol 1 (abstract C-299) Waverly Press, Baltimore, p 78
36. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V (1987) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5: 354
37. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, Ali MK (1982) Clinical and pharmacological investigation of the effects of tocopherol on Adriamycin cardiotoxicity. Ann NY Acad Sci 33: 411
38. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU (1984) Combined chemotherapy of metastatic breast cacinoma with cyclophosphamide, Adriamycin, and Peptichemio. Cancer 53: 1836
39. Theriault RL, Hortobagyi GN, Kau SW, Holmes FA, Hug V, Fraschini G, Jabboury K, Buzdar AU (1988) Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer 62: 2105
40. Hortobagyi GN, Buzdar AU, Frye D, Hug V, Fraschini G, Ames FC, Montague E, Gutterman JU, Martin RG (1987) Combined antiestrogen and cytotoxic therapy with Pseudomonas vaccine immunotherapy for metastatic breast cancer: a prospective, random trial. Cancer 60: 2596
41. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552
42. Cox DR (1972) Regression models and life tables. J R Statist Soc B 34: 187
43. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47
44. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710
45. Buzdar AU, Marcus C, Smith TL, Blumenschein GR (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761
46. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L (1987) Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 82: 1109
47. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP (1982) Doxorubicin cardiotoxicity. Cancer Treat Rev 9: 149
48. Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D, D'Angelo T, Rosenberg SA (1983) Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post-surgical adjuvant treatment of patients with soft tissue sarcoma. Cancer 52: 51
49. Henderson IC, Frei E (1980) Adriamycin cardiotoxicity. Am Heart J 99: 671
50. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN (1996) Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Arch Intern Med 156: 882
51. Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML (1976) The cardiotoxicity of Adriamycin and daunomycin in children. Cancer 37: 1070
52. Goorin AM, Borrow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, Cohen H, Jaffe N (1981) Congestive heart failure due to Adriamycin cardiotoxicity: its natural history in children. Cancer 47: 2810
53. Stienherz LJ, Stienherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672
54. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808
55. Goorin AM, Chauvenet AR, Perez-Atayade AR, Cruz J, McKone R, Lipshultz SE (1990) Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116: 144
56. Ali MK, Ewer MS, Gibbs HR, Swafford J, Graff KL (1994) Late doxorubicin-associated cardiotoxicity in children. Cancer 74: 182
57. Lipshultz SE (1996) Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children (editorial). J Clin Oncol 14: 328